|
|||||
![]() |
|
Business advisory firm FTI Consulting (NYSE:FCN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales were flat year on year at $943.7 million. The company’s full-year revenue guidance of $3.71 billion at the midpoint came in 1.1% above analysts’ estimates. Its GAAP profit of $2.13 per share was 27.1% above analysts’ consensus estimates.
Is now the time to buy FCN? Find out in our full research report (it’s free).
FTI Consulting’s second quarter results drew a positive market response as the company delivered solid performance despite flat year-over-year sales and notable headwinds. Management cited ongoing challenges in the Technology and Economic Consulting segments, with CEO Steven Gunby highlighting the impact of fewer large M&A deals and regulatory shifts affecting antitrust work. Conversely, Corporate Finance & Restructuring and Strategic Communications reached new highs, buoyed by increased demand for restructuring services and corporate reputation work. Gunby emphasized, “We are having a solid year, not only while fighting off the headwinds but while reinvesting in our businesses that we believe in.”
Looking to the remainder of the year, management’s guidance is underpinned by expectations of gradual improvement in certain challenged segments, ongoing investment in hiring, and the strength of diversified service lines. CFO Ajay Sabherwal noted that Technology and Economic Consulting are likely to remain under pressure, but expressed confidence in the resilience of FTI Consulting’s business model and the potential recovery of EBITDA margins. Gunby added that the firm’s commitment to attracting top talent and expanding expertise positions the company to capitalize on future market opportunities, stating, “If we can have this solid a year in the face of all the headwinds we faced this year, while at the same time, reinvesting in the businesses that we believe in, doesn’t that speak to the amazing strength of this institution?”
Management attributed second quarter performance to strong execution in select business lines and resilience amid sector-specific downturns, while reaffirming ongoing investments despite short-term impacts on profitability.
Management expects the rest of the year to be shaped by continued investment in talent, stabilization in challenged segments, and persistent macroeconomic and regulatory uncertainty.
Looking ahead, our analyst team will be monitoring (1) the pace at which new senior and academic hires contribute to revenue growth, (2) stabilization or recovery in Technology and Economic Consulting as regulatory and market dynamics evolve, and (3) sustained strength in restructuring and strategic communications demand amid ongoing macroeconomic uncertainty. The impact of regulatory trends and talent investments on margins will remain key indicators of execution.
FTI Consulting currently trades at $173.49, up from $167.53 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Sep-11 | |
Sep-11 | |
Sep-10 | |
Sep-09 | |
Sep-08 | |
Sep-03 | |
Sep-02 | |
Sep-01 | |
Aug-31 | |
Aug-19 | |
Aug-18 | |
Aug-15 | |
Aug-14 | |
Aug-13 | |
Aug-13 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite